CUREMARK
LIVE

Serial Number

90322325

Owner

Curemark, LLC

Attorney

Nicole K. McLaughlin

First Use Date

Jan 1, 2004

Filing Date

Nov 16, 2020

Add to watchlist:

No watchlists yet
View on USPTO

CUREMARK Trademark

Serial Number: 90322325 • Registration: 6573013

CUREMARK is a trademark filed by Curemark, LLC on November 16, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Curemark, LLC (66 trademarks)

Suite 1B
Yonkers, NY 10704

Entity Type: 16

Trademark Details

Filing Date

November 16, 2020

Registration Date

November 30, 2021

First Use Anywhere

January 1, 2004

First Use in Commerce

January 1, 2004

Published for Opposition

September 14, 2021

Goods & Services

Pharmaceutical preparations and substances for the diagnosis, treatment and prevention of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Antibacterial, antiviral and antifungal preparations for skin and wound healing; disinfectants and antiseptics; antimicrobial cleansers for sanitation purposes; Medical assays for testing of bodily fluids and tissues for testing of enzymes in humans; biological preparations for medical testing; diagnostic preparations for medical purposes; testing kits comprised of medical diagnostic reagents and assays for testing enzymes and body fluids for use in disease detection; medical diagnostic reagents and assays for testing of enzymes and body fluids; chemical preparations for medical testing; diagnostic biomarker reagents for medical testing; all the foregoing for the diagnosis and treatment of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders

Medical testing for diagnostic and treatment purposes; Medical consultations; medical testing for diagnostic treatment purposes in the fields of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; medical testing for diagnostic treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Medical diagnostic testing, monitoring and reporting services; performing diagnosis of diseases; Health care services, namely, the administration of medical assays for the detection of enzymes in humans

Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical research; Development of pharmaceuticals and medical devices for others; Providing temporary use of non-downloadable computer software that allows users to make determinations regarding neurological diseases, specifically baseline staging, data gathering and monitoring of early, middle and late stage neurological diseases; Design and development of medical assays for others; clinical research and development of treatments for viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; clinical research and development of treatments for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; clinical research and development of treatments for antibacterial, antiviral, and antifungal preparations for skin and wound healing; clinical research and development of disinfectants, antiseptics and antimicrobial cleansers for sanitation purposes; medical and scientific research services in the field of digestion and detection of enzymes or biological substances in the body

Filing History

REGISTERED-PRINCIPAL REGISTER
Nov 30, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 14, 2021 NPUB
PUBLISHED FOR OPPOSITION
Sep 14, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 6, 2021 CNSA
ASSIGNED TO EXAMINER
Jul 12, 2021 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 9, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 9, 2021 CRFA
ASSIGNED TO LIE
Jul 1, 2021 ALIE
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 3, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 3, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 3, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 3, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 3, 2021 COAR
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 29, 2021 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 26, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 26, 2021 GNSL
SUSPENSION LETTER WRITTEN
Apr 26, 2021 CNSL
ASSIGNED TO EXAMINER
Apr 26, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 15, 2021 NWOS
NEW APPLICATION ENTERED
Nov 19, 2020 NWAP